Ixico Regulatory News (IXI)

9 Jan 2006 07:01

Phytopharm PLC09 January 2006 PHYTOPHARM PLC AND SCHERING-PLOUGH ANIMAL HEALTH ENTER INTO A MARKETING AND DISTRIBUTION AGREEMENT FOR PHYTOPICA(TM) GODMANCHESTER, Cambridgeshire, U.K. (January 9th 2006) - Phytopharm plc (LSE:PYM; NASDAQBB: PHYOF; PHYOY) ("Phytopharm") announces today that it has enteredinto an exclusive global marketing and distribution agreement with Schering-Plough Animal Health (Schering-Plough) for Phytopica(TM), a plant-based productclinically proven to promote healthy skin and coat in dogs. Phytopica(TM) is anatural product combining the beneficial effects of 3 plants and provides anovel 3 in 1 approach to help maintain a normal healthy immune system, supportnormal white cell function and provide anti-oxidant benefits. Maintenance of ahealthy skin and coat condition are of major importance to canine general healthand quality of life. Under the terms of the agreement, Phytopharm will beresponsible for the manufacture and sale of Phytopica(TM) to Schering-Plough.Schering-Plough will be responsible for the global sales, marketing anddistribution of Phytopica(TM). Dr Richard Dixey, Chief Executive Officer of Phytopharm, said: "We are delightedto enter this agreement with one of the world's leading animal health companies.Phytopica(TM) has already been introduced to veterinary dermatologists, and withSchering-Plough's global presence we look forward to maximizing the potentialfor the product." -ENDS- Company Contact: U.K. Investor relations contactPhytopharm, plc Financial DynamicsRichard Dixey David Yates/Ben Atwell+44 7867 782000 +44 207 831 3113www.phytopharm.com PHYTOPHARM PLCPhytopharm is focused on the research and development of novel pharmaceuticaland functional food products based on clinical and pre-clinical data generatedfrom medicinal plant extracts. The Company has seven development programmes infour disease areas: neurodegeneration, obesity and metabolic disease,dermatology and inflammation and has a portfolio of two marketed veterinaryproducts. More information concerning Phytopharm's activities can be found on its web siteat http://www.phytopharm.com This press release may contain forward-looking statements within the meaning ofSection 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S.Securities Exchange Act of 1934 with respect to the financial condition, resultsand business achievements/performance of Phytopharm and certain of the plans andobjectives of its management. These statements are statements that are nothistorical facts. Words such as "should", "expects", "anticipates", "estimates", "believes" or similar expressions, as they relate to Phytopharm, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflectPhytopharm's current expectations and assumptions as to future events andcircumstances that may not prove accurate. There is no guarantee that theexpected events, trends or results will actually occur. Any changes in suchassumptions or expectations could cause actual results to differ materially fromcurrent expectations. This information is provided by RNS The company news service from the London Stock Exchange